Left to right: John Gray (President and CEO of HDA), Mike Muzetras (Senior National Account Manager at Upsher-Smith), Mike McBride (VP Partner Relations at Upsher-Smith), Brad Leonard (Associate VP of National Accounts at Upsher-Smith), Dave ... Read More
Two-day, Annual Event Took Place at its Maple Grove, Minnesota Headquarters
Maple Grove, MN and NorthChesterfield, VA – May 23, 2019 —Upsher-Smith Laboratories, LLC (Upsher-Smith) recently hosted the National Alliance of State Pharmacy Associations (NASPA)/Pharmacists Mutual ... Read More
Maple Grove, MN – May 3, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of its newly redesigned website for Qudexy® XR (topiramate) Extended-Release Capsules. The enhanced website offers support tools and educational resources for ... Read More
Osaka, Japan – March 27, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) ... Read More
Maple Grove, MN – March 27, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Fluoxetine Tablets, USP, 10 and 20 mg. Upsher-Smith’s product is AB-rated to the branded product, Prozac® (fluoxetine) tablets, ... Read More
Osaka, Japan – March 6, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) ... Read More
Osaka, Japan – February 15, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for three compounds with six strengths ... Read More
